12:00 Arizona

This webinar will present findings from a planned interim analysis of the Phase 3 FORTIFY trial, a randomized clinical trial evaluating the investigational therapy BBP-418 in individuals with LGMD2I/R9, including recently presented patient reported outcomes and cardiac data. This program will include a scientific overview of LGMD2I/R9, including current understanding of disease pathophysiology, natural history, and clinical assessment. Attendees will gain insight into the scientific rationale and clinical data generated from the FORTIFY program.